Education
About Us
Working with TipRanks
Follow Us
VHT - ETF AI Analysis
Top Page
Vanguard Health Care ETF (VHT)
Rating:66Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several key holdings, such as Johnson & Johnson and AbbVie, have delivered strong year-to-date performance, supporting the ETF's overall returns.
Low Expense Ratio
The ETF has a very low expense ratio, making it cost-efficient compared to many other funds.
Focused Sector Exposure
The ETF's heavy focus on the health care sector provides targeted exposure to a historically resilient industry.
Negative Factors
Underperforming Holdings
Some top holdings, like UnitedHealth and Pfizer, have lagged in performance, potentially dragging down overall returns.
High Sector Concentration
With over 95% of the portfolio in health care, the ETF is highly exposed to risks specific to this sector.
Limited Geographic Diversification
The ETF is heavily concentrated in U.S. companies, offering little exposure to international markets.
VHT vs. SPDR S&P 500 ETF (SPY)
AUM17.37B
RegionNorth America
Expense Ratio0.09%
Beta0.53
IssuerVanguard
Inception DateJan 26, 2004
Dividend Yield1.58%
Asset ClassEquity
Index TrackedMSCI US IMI 25/50 Health Care
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume288,287
30 Day Avg. Volume257,529
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
327.10Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering413
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VHT Summary
The Vanguard Health Care ETF (VHT) is an investment fund that focuses on the health care sector, including companies in pharmaceuticals, biotechnology, medical devices, and health care services. It follows the MSCI US IMI 25/50 Health Care Index and includes well-known companies like Eli Lilly & Co and Johnson & Johnson. This ETF is a good option for investors looking to benefit from the growth potential of the health care industry, driven by aging populations and advancements in medical technology. However, new investors should be aware that the ETF’s performance is closely tied to the health care sector, which can be affected by regulatory changes or market fluctuations.
How much will it cost me?The Vanguard Health Care ETF (VHT) has an expense ratio of 0.09%, which means you’ll pay $0.90 per year for every $1,000 invested. This is lower than average because it is a passively managed fund that tracks an index, keeping costs low for investors.
What would affect this ETF?The Vanguard Health Care ETF (VHT) could benefit from long-term trends like aging populations, increased global health care spending, and advancements in medical technology, which drive demand for pharmaceuticals, biotechnology, and medical devices. However, it may face challenges from regulatory changes, patent expirations for major drug companies, or economic downturns that could impact health care budgets and innovation funding. Its focus on U.S.-based health care companies means it is particularly sensitive to domestic policy shifts and market conditions.
VHT Top 10 Holdings
The Vanguard Health Care ETF (VHT) leans heavily into the health care sector, with Eli Lilly leading the charge thanks to its strong financial performance and robust growth outlook. Johnson & Johnson is another steady contributor, benefiting from strategic initiatives and a bullish trend. However, UnitedHealth is dragging the fund slightly, facing challenges in its Medicare and Medicaid segments. Meanwhile, Abbott Laboratories and Thermo Fisher show mixed signals, with bearish momentum tempering their long-term growth potential. Overall, the fund’s U.S.-centric focus and concentration in health care giants position it well for resilience but leave little room for diversification.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 12.39% | $2.62B | $984.63B | 37.60% | 72 Outperform | |
| AbbVie | 4.85% | $1.03B | $389.14B | 24.73% | 66 Neutral | |
| Johnson & Johnson | 4.42% | $937.25M | $492.24B | 40.05% | 78 Outperform | |
| UnitedHealth | 4.02% | $851.58M | $309.81B | -32.14% | 72 Outperform | |
| Merck & Company | 3.75% | $794.30M | $266.67B | 7.77% | 80 Outperform | |
| Abbott Laboratories | 3.21% | $680.54M | $219.88B | 12.68% | 73 Outperform | |
| Thermo Fisher | 3.19% | $676.81M | $229.63B | 13.76% | 72 Outperform | |
| Intuitive Surgical | 2.94% | $623.63M | $200.78B | 11.46% | 78 Outperform | |
| Amgen | 2.66% | $564.17M | $172.70B | 25.99% | 77 Outperform | |
| Gilead Sciences | 2.24% | $473.65M | $146.77B | 33.91% | 78 Outperform |
VHT Technical Analysis
Positive
―
Price Trends
282.64
Positive
270.00
Positive
257.55
Positive
Market Momentum
2.19
Positive
65.05
Neutral
70.12
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VHT, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 287.41, equal to the 50-day MA of 282.64, and equal to the 200-day MA of 257.55, indicating a bullish trend. The MACD of 2.19 indicates Positive momentum. The RSI at 65.05 is Neutral, neither overbought nor oversold. The STOCH value of 70.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VHT.
VHT Peer Comparison
Comparison Results
Performance Comparison
VHT
Vanguard Health Care ETF
293.91
40.87
16.15%
VGT
Vanguard Information Technology ETF
―
―
―
XLK
Technology Select Sector SPDR Fund
―
―
―
XLF
Financial Select Sector SPDR Fund
―
―
―
XLV
Health Care Select Sector SPDR Fund
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents